TABLE 3.
Covariate analysis
| Characteristica | Pharmacokinetic parameter(s) | Objective function value | IIVb CL (%) |
|---|---|---|---|
| Structural model | 6,569.0c | 98.3 | |
| Allometric model | CL, V1, V2, Q | ||
| Current body wt | 6,455.1 | 67.6 | |
| Impact of age | V1 | ||
| GA | 6,454.9 | ||
| PNA | 6,451.9 | ||
| PMA | 6,453.2 | ||
| Impact of age | V2 | ||
| GA | 6,455.1 | ||
| PNA | 6,452.3 | ||
| PMA | 6,453.7 | ||
| Impact of renal maturation | CL | ||
| Birth wt | 6,442.0 | ||
| GA | 6,438.7 | ||
| PNA | 6,425.2 | ||
| PMA | 6,399.5 | 43.6 | |
| Birth wt and PNA | 6,396.2 | ||
| GA and PNA | 6,388.4 | 42.5 | |
| Impact of renal function | CL | ||
| Serum creatinine | 6,429.3 | ||
| Impacts of renal maturation and renal function | CL | ||
| GA, PNA, and serum creatinine | 6,371.3 | 36.9 | |
| Impacts of renal maturation, renal function, and comedication | CL | ||
| GA, PNA, serum creatinine, and diuretics | 6,371.4 | ||
| GA, PNA, serum creatinine, and caffeine | 6,369.2 | ||
| GA, PNA, serum creatinine, and teicoplanin | 6,371.0 | ||
| GA, PNA, serum creatinine, and amoxicillin-clavulanic acid | 6,366.8 | ||
| GA, PNA, serum creatinine, and nystatin | 6,370.9 | ||
| GA, PNA, serum creatinine, and inotropic agents | 6,363.8 | 34.5 |
a
GA, gestational age; PNA, postnatal age; PMA, postmenstrual age.
b
IIV, interindividual variability.
c
OFV values of model with significant improvement are indicated in boldface.